The Company is also conducting a late Phase 2 study of the drug for chronic, or long term, spinal cord injury.
Demyelinated axons are alive, but can no longer conduct impulses.
Thus, patients with MS experience a range of neurological deficits, including weakness, paralysis, involuntary spasms, impaired vision, and loss of control of bodily functions. By closing the exposed potassium channels, fampridine permits the axon to transmit impulses again, resulting in increased neurological function. Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury and related neurological conditions, including multiple sclerosis.